Cargando…

Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma

Cholangiocarcinoma has a poor prognosis and is refractory to conventional chemotherapy and radiation therapy. Improving survival of patients with advanced cholangiocarcinoma urgently requires the development of new effective targeted therapies in combination with chemotherapy. We previously develope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Seulki, Lee, Tae Sup, Song, In Ho, Kim, A-Ram, Lee, Yoon-Jin, Kim, Haejung, Hwang, Haein, Jeong, Mun Sik, Kang, Seung Goo, Hong, Hyo Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293259/ https://www.ncbi.nlm.nih.gov/pubmed/28166242 http://dx.doi.org/10.1371/journal.pone.0170078

Ejemplares similares

L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation
por: Kim, Haejung, et al.
Publicado: (2017)

A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model
por: Lee, Eung Suk, et al.
Publicado: (2012)

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020)

Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma
por: Ishii, Masatsugu, et al.
Publicado: (2022)

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
por: Franssen, Stijn, et al.
Publicado: (2023)

Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma
por: Yang, So Mi, et al.
Publicado: (2023)

Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM
por: Cho, Seulki, et al.
Publicado: (2016)

Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern
por: Chung, Taek, et al.
Publicado: (2022)

Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
por: Tsunematsu, Masashi, et al.
Publicado: (2019)

Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
por: Takayanagi, Ryosuke, et al.
Publicado: (2017)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
por: Suksawat, Manida, et al.
Publicado: (2022)

Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma
por: Seo, Jung Woong, et al.
Publicado: (2020)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

Intrahepatic cholangiocarcinoma arising in Caroli's disease
por: Jang, Min Hye, et al.
Publicado: (2014)

Effect of age on the prognosis of intrahepatic cholangiocarcinoma
por: Kim, Jung Hun, et al.
Publicado: (2023)

An antibody against L1 cell adhesion molecule inhibits cardiotoxicity by regulating persistent DNA damage
por: Nam, Jae-Kyung, et al.
Publicado: (2021)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice
por: Park, Jaeoh, et al.
Publicado: (2020)

Genetic features associated with (18)F-FDG uptake in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2019)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series
por: Kang, Myoung Hee, et al.
Publicado: (2014)

A Case of Clonorchiasis with Focal Intrahepatic Duct Dilatation Mimicking an Intrahepatic Cholangiocarcinoma
por: Kim, Bong Gap, et al.
Publicado: (2011)

Reversal of Jaundice in Two Patients with Inoperable Cholangiocarcinoma Treated with Cisplatin and Gemcitabine Combination
por: Criel, Maarten, et al.
Publicado: (2012)

Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
por: Inoue, Tadahisa, et al.
Publicado: (2022)

Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Jeong, Seogsong, et al.
Publicado: (2016)

Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
por: Tomooka, Fumimasa, et al.
Publicado: (2023)

Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma
por: Jeong, Seorin, et al.
Publicado: (2017)

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020)

HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in Cholangiocarcinoma
por: Gao, Kun, et al.
Publicado: (2021)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma
por: Yang, Beng, et al.
Publicado: (2018)

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
por: Zhang, Yu-Qing, et al.
Publicado: (2023)

Complex Liver Resections for Intrahepatic Cholangiocarcinoma
por: Reese, Tim, et al.
Publicado: (2021)

Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma
por: Zheng, Wen-Heng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gk16ccr0a2o1r47pj4a19ol53g